Date Filed | Type | Description |
03/22/2022 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Disposed of 7,588,395 shares
@ $0 Disposed/sold 22,685 restricted stock units
@ $0 Disposed/sold 7,500 options to buy
@ $2.93, valued at
$22k
Disposed/sold 85,760 options to buy
@ $3.66, valued at
$313.9k
|
|
02/15/2022 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Converted 2,422,222 shares
@ $1.8, valued at
$4.4M
Converted 436 convertible preferred
@ $1.8, valued at
$784.8 |
|
01/31/2022 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Granted 85,760 options to buy
@ $0 Granted 15,369 restricted stock units
@ $0 Exercised 7,684 restricted stock units
@ $0 |
|
11/22/2021 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Bought 100,000 shares
@ $3.06, valued at
$306k
|
|
11/15/2021 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Bought 100,000 shares
@ $3.2, valued at
$320k
|
|
11/09/2021 |
4
| KOTLER KEVIN (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Bought 257,800 shares
@ $3.47, valued at
$894.6k
|
|
08/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/04/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/04/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
08/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/23/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/19/2020 |
4
| Broadfin Healthcare Master Fund Ltd (Director) has filed a Form 4 on BIODELIVERY SCIENCES INTERNATIONAL INC
Txns:
| Exercised 10,623 shares
@ $2.93, valued at
$31.1k
Converted 10,623 options
@ $2.93, valued at
$31.1k
|
|
02/24/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Broadfin Capital, LLC reports a 0% stake in Zyla Life Sciences |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Broadfin Capital, LLC reports a 4.6% stake in Aclaris Therapeutics, Inc. |
02/13/2020 |
SC 13G/A
| Broadfin Capital, LLC reports a 0% stake in Adamas Pharmaceuticals, Inc. |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/22/2020 |
SC 13D/A
| Broadfin Capital, LLC reports a 6.4% stake in Strata Skin Sciences, Inc. |
01/15/2020 |
3
| Broadfin Healthcare Master Fund Ltd (10% Owner) has filed a Form 3 on NOVELION THERAPEUTICS INC. |
01/15/2020 |
SC 13G/A
| Broadfin Capital, LLC reports a 12.9% stake in Novelion Therapeutics Inc. |
12/23/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|